Growth factor and cytokine interactions in myogenesis Part II Expression of IGF binding proteins and protein kinases essential for myogenesis in mouse C2C12 myogenic cells exposed to TNF- alpha and IFN- gamma

• Autorzy: Wieteska-Skrzeczynska W. , Grzelkowska-Kowalczyk K. , Rejmak E.
• Języki publikacji: EN

Abstrakty

EN

The aim of the study was to examine potential interactions among IGF-I and proinflammatory cytokines, TNF-α and IFN-γ, in the regulation of local IGF-I bioavailability and cellular proteins mediating myogenic signals. We investigated levels of IGFBP-4, -5, -6, protein kinase Czeta (PKCζ), p38 and extracellular signal-regulated kinase (ERK1/2) in differentiating mouse C2C12 myoblasts. IGF-I significantly stimulated expression of IGFBP-5. TNF-α and IFN-γ attenuated the expression of IGFBP-4 and -6 under basal conditions and in the presence of IGF-I, and inhibited IGF-I-induced IGFBP-5 expression during 5-day myogenesis. TNF-α and IFN-γ markedly attenuated p38 expression in the presence of IGF-I on the 5th day of myogenesis. When combined with IGF-I the cytokines exerted opposite effects on the PKCζ level, i.e. TNF-α caused an increase, whereas IFN-γ reduced the cellular content of this kinase. Exposition of C2C12 myoblasts to IGF-I or cytokines led to the stimulation of ERK1/2 phosphorylation; however, both TNF-α and IFN-γ exerted an inhibitory effect on the activation of ERK1/2 in myoblasts cultured in the presence of IGF-I. We concluded as follows: i) TNF-α and IFN-γ present in the extracellular environment of differentiating C2C12 myoblasts can alter the local bioavailability of IGF-I by inhibiting the expression of IGFBP-4, -5, and -6, ii) the decrease in p38 expression and ERK1/2 phosphorylation in C2C12 myoblasts exposed to cytokines can lead to disturbances in IGF-I-regulated myogenesis.

• Wydawca: -
• Czasopismo: Polish Journal of Veterinary Sciences
• Rocznik: 2011
• Tom: 14
• Numer: 3
• Opis fizyczny: p.425-431,fig.,ref.

Twórcy

autor

Wieteska-Skrzeczynska W.

• Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences(SGGW)Nowoursynowska 159, 02-776 Warsaw, Poland

autor

Grzelkowska-Kowalczyk K.

autor

Rejmak E.

Bibliografia

• Adams GR (2010) Insulin-like growth factor I signaling in skeletal muscle and the potential for cytokine interactions. Med Sci Sports Exerc 42: 50-57.
• Adi S, Bin-Abbas B, Wu NY, Rosenthal SM (2002) Early stimulation and late inhibition of extracellular signal-regulated kinase 1/2 phosphorylation by IGF-I: a potential mechanism mediating the switch in IGF-I action on skeletal muscle cell differentiation. Endocrinology 143: 511-516.
• De Alvaro C, Nieto-Vazquez I, Rojas JM, Lorenzo M (2008) Nuclear exclusion of forkhead box O and Elk1 and activation of nuclear factor-kB are required for C2C12-RasV12C40 myoblast differentiation. Endocrinology 149: 793-801.
• de Thonel A, Ferraris SE, Pallari HM, Imanishi SY, Kochin V, Hosokawa T, Hisanaga S, Sahlgren C, Eriksson JE (2010) Protein kinase Czeta regulates Cdk5/p25 signaling during myogenesis. Mol Biol Cell 21: 1423-1434.
• Duan C, Ren H, Gao S (2010) Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins: roles in skeletal muscle growth and differentiation. Gen Comp Endocrinol 167: 344-351.
• Fernandez-Celemin L, Pasko N, Blomart V, Thissen J-P (2002) Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-α. Am J Physiol Endocrinol Metab 283: E1279-E1290.
• Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23: 824-854.
• Grzelkowska-Kowalczyk K, Wieteska-Skrzeczyńska W (2010) Treatment with TNF-α and IFN-γ alters the activation of SER/THR protein kinases and the metabolic response to IGF-I in mouse C2C12 myogenic cells. Cell Mol Biol Lett 15: 13-31.
• Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS (2002) A central role for JNK in obesity and insulin resistance. Nature 420: 333-336.
• Igarashi M, Hirata A, Yamaguchi H, Sugae N, Kadamoto-Antsuki Y, Nozaki H, Jimbu Y, Tominaga M (2007) Characterization of activation of MAP kinase superfamily in vasculature from diabetic rats. J Atheroscler Thromb 14: 235-244.
• Jacobi SK, Gabler NK, Ajuwon KM, Davis JE, Spurlock ME (2006) Adipocytes, myofibers, and cytokine biology: new horizons in the regulation of growth and body composition. J Animal Sci 84: E140-E149.
• Jennische E, Hall CM (2000) Expression and localisation of IGF-binding protein mRNAs in regenerating rat skeletal muscle. APMIS 108: 747-755.
• Jo C, Jang BG, Jo SA (2009) MEK1 plays contrary stage-specific roles in skeletal myogenic differentiation. Cell Signal 21: 1910-1917.
• Lang CH, Frost RA (2002) Role of growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins in the catabolic response to injury and infection. Curr Opin Clin Nutr Metab Care 5: 271-279.
• Mourkioti F, Rosenthal N (2005) IGF-I, inflammation and stem cells: interactions during muscle regeneration. Trends Immunol 26: 535-542.
• Ning Y, Schuller AG, Bradshaw S, Rotwein P, Ludwig T, Frystyk J, Pintar JE (2006) Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5. Mol Endocrinol 20: 2173-2186.
• Nystrom G, Pruznak A, Huber D, Frost RA, Lang CH (2009) Local insulin-like growth factor I prevents sepsis-induced muscle atrophy. Metabolism 58: 787-797.
• Oksbjerg N, Gondret F, Vestergaard M (2004) Basic principles of muscle development and growth in meat-producing mammals as affected by the insulin-like growth factor (IGF) system. Domest Anim Endocrinol 27: 219-240.
• Paye JM, Forsten-Williams K (2006) Regulation of insulin-like growth factor-I (IGF-I) delivery by IGF binding proteins and receptors. Ann Biomed Eng 34: 618-632.
• Plaisance I, Morandi C, Murigande C, Brink M (2008) TNF-alpha increases protein content in C2C12 and primary myotubes by enhancing protein translation via the TNF-R1, PI3K, and MEK. Am J Physiol Endocrinol Metab 294: E241-E250.
• Schertzer JD, Gehrig SM, Ryall JG, Lynch GS (2007) Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice. Am J Pathol 171: 1180-1188.
• Solomon AM, Bouloux PM (2006) Modifying muscle mass - the endocrine perspective. J Endocrinol 191: 349-360.
• Thissen J-P (2007) How proinflammatory cytokines may impair growth and cause muscle wasting. Horm Res 67: 64-70.
• Tiffin N, Adi S, Stokoe D, Wu NY, Rosenthal SM (2004) Akt phosphorylation is not sufficient for insulin-like growth factor-stimulated myogenin expression but must be accompanied by down-regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase phosphorylation. Endocrinology 145: 4991-4996.
• Tripathi G, Salih DA, Drozd AC, Cosgrove RA, Cobb LJ, Pell JM (2009) IGF-independent effects of insulin-like growth factor binding protein-5 (igfbp5) in vivo. FASEB J 23: 2616-2626.
• Vary TC, Deiter G, Lang CH (2004) Diminished ERK 1/2 and p38 MAPK phosphorylation in skeletal muscle during sepsis. Shock 22: 548-554.
• Yin P, Xu Q, Duan C (2004) Paradoxical actions of endogenous and exogenous insulin-like growth factor-binding protein-5 revealed by RNA interference analysis. J Biol Chem 279: 32660-32666.